The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Abstract Fibroblast growth factor receptor (FGFR)−2 can be inhibited by FGFR-selective or non-selective tyrosine kinase inhibitors (TKIs). Selective TKIs are approved for cholangiocarcinoma (CCA) with FGFR2 fusions; however, their application is limited by a characteristic pattern of adverse events...

Повний опис

Збережено в:

Бібліографічні деталі
Автори:	Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, Aaron Stahl, Yvonne Rasen, Christine Geisler, Kristina Ruhm, Marion Klaumuenzer, Thales Kronenberger, Stefan A. Laufer, Holly Sundberg-Malek, Khac Cuong Bui, Marius Horger, Saskia Biskup, Klaus Schulze-Osthoff, Markus Templin, Nisar P. Malek, Antti Poso, Michael Bitzer
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Nature Portfolio 2024-02-01
Серія:	Nature Communications
Онлайн доступ:	https://doi.org/10.1038/s41467-024-45247-6
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma

Схожі ресурси